in combination with a 5HT3 receptor antagonist and corticosteroid, is superior to a 5-HT3 receptor antagonist and cortico steroid alone in providing protection against chemotherapy-induced nausea and vomiting for the entire at-risk period in patients receiving moderately or highly emetogenic chemotherapy